Inhibitory effect of rhubarb on intestinal α-glucosidase activity in type 1 diabetic rats

KJ Hou*, CJ Lin, C Chen, BT Wu, XH Wang and D Zhu
Traditional Chinese Medicine Hospital of Shantou, Affiliated Hospital of Traditional Chinese Medicine University of Guangzhou, Shantou City, China

*For correspondence: Email: kaijianhou@126.com

Abstract

**Purpose:** To investigate the inhibitory effect of rhubarb on α-glucosidase activity in the small intestine of rats with type 1 diabetes.

**Methods:** Type 1 diabetic rat model was established by intraperitoneally injecting 30 male SD rats with 1 % streptozocin (STZ). Rats with fasting blood glucose > 11 mmol/L (24) were used for the study. The rats were randomly divided into three equal groups including control, acarbose and rhubarb groups. Arcabose® (20 mg/kg /day) and rhubarb (100 mg/kg /day) were given by intra-gastric route via insertion of the cannula through the esophagus. Daily fasting blood glucose and daily postprandial glucose levels were assayed for all groups. On day 6, postprandial blood glucose, blood levels of C-peptide and insulin, and intestinal α-glucosidase were also determined.

**Results:** There were no significant differences in levels of C-peptide, insulin and fasting blood glucose between control, Acarbose® and rhubarb groups (p > 0.05). However, α-glucosidase activity at 0, 30, 60 and 120 min in the rhubarb group was 1759.2, 1812.8, 1379.8 and 772.1 U, respectively,) while in the Acarbose® group it was 178.6, 1260.1, 1126.5, 599.2 U, respectively. α-Glucosidase activity in both groups initially showed an increase (p < 0.05), followed by a decline from 60 to 120 min (p < 0.05). After 120 min, α-glucosidase activity in each of the two groups was significantly decreased compared with untreated control (1200 U) (p < 0.05).

**Conclusion:** The inhibitory effect of rhubarb on intestinal α-glucosidase activity of Type 1 diabetic rats is comparable to that of Arcarbose®. This suggests that this plant may have clinically potent anti-diabetic properties.

**Keywords:** Type 1 diabetes, α-Glucosidase activity, Acarbose®, Rhubarb, Postprandial glucose level

INTRODUCTION

As a serious and chronic metabolic disorder, diabetes mellitus can be reflected by the increased levels of hemoglobin, fasting blood glucose and postprandial blood glucose [1]. Diabetic patients manifest impaired glucose tolerance which is a consequence defects in the function or secretion of insulin. Impaired glucose tolerance results in postprandial hyperglycemia [2]. The α-glucosidase inhibitors (Miglitol®, Voglibose® and Acarbose®) are used for improving insulin sensitivity and decreasing postprandial hyperglycemia, through suppressing intestinal absorption of carbohydrates [3]. Type 1 diabetes, which is caused by insulin deficiency can be treated with α-glucosidase inhibitors [4]. Acarbose® is a popular α-glucosidase inhibitor [5]. α-Glucosidase activity has unique advantages in the treatment of diabetes mellitus, especially in reducing postprandial blood glucose. Acarbose® treatment, which is
recommended by Asia Pacific Diabetes Drug Guide, is the first-line therapy of postprandial blood glucose reduction [6].

However, the use of Acarbose® is associated with problems of intolerance. In some patients, it produces intestinal problems, one of which is flatulence [7]. Therefore, the development of novel drugs with high activity and low mammalian toxicity is urgently needed. In this regard, the high and efficacy of herbs-derived drugs have attracted more and more attentions [8]. With the antibacterial, anti-tumor, anti-mutagenic and purgative activities, dried rhubarb rhizome was widely used in the traditional Chinese medicine. The main bioactive constituents of rhubarb are anthraquinone derivatives, which can induce apoptosis, inhibit cellular proliferation and prevent metastasis [9]. However, the anti-diabetic properties of rhubarb have not been well studied [10].

This study was carried out to investigate the effects of rhubarb on intestinal α-glucosidase and other indices (postprandial blood glucose, C-peptide protein, insulin and fasting blood glucose) in an SD rat model of type 1 diabetes.

EXPERIMENTAL

Materials

Rhubarb (fine powder, Batch no. 110757200206; Xiankangwei Biological Engineering Co., Ltd. China) was preserved at room temperature. Acarbose (H19990205) was a product of Bayer Healthcare Pharmaceutical Company, Beijing. Alpha-glucosidase activity reagent (MAK123) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Streptozotocin (STZ, 1 %) was prepared in 0.1mol/L citric acid buffer, pH 4.3, and was preserved at 4 °C.

Animal model

Thirty healthy male SD rats (mean weight = 171.2 ± 8.6 g) were provided by Guangdong Medical Experimental Animal Center (China). The rats were kept in SPF animal house in Guangdong Medical Experimental Animal Center (license number: SYXK (Guangdong 2013-0002). They were housed in numbered cages in a room with a 10h light/14h dark cycle at 23 ± 3 °C and moisture level of 55 ± 15 %. Pellet feed containing 33.9 % starch, and water were provided ad libitum. The rats were fasted overnight (12 h) and given intraperitoneal injection of 1 % STZ solution (6 mL/kg body weight). After 7 days, the fasting blood glucose of the rats was measured after 5h fast. Rats with fasting blood- glucose ≥ 11.0 mmol / L were chosen as experimental models. This research was approved by the Animal Ethics Committee of Guangdong Provincial experimental Animal Center (approval ref no. B201504-9). All the animal experiments were performed according to “Guidelines for Ethical Conduct in the Care and Use of Animals” [11].

Animal experiments

Twenty-four model rats were randomly divided into control group (given saline), Acarbose group, and rhubarb group. Each group had 8 rats. In the acarbose group, rats were subjected to intra-gastric administration of 20 mg Acarbose® /kg body weight/day. Rats in the rhubarb group received 100 mg rhubarb/kg body weight/day, also via the intra-gastric route through insertion of the cannula via the esophagus, the dose were determined according the previous studies [12,13]. In both groups, the dose selection was based on estimated intake for a 60 kg reference man. In the control group, rats received intragastric saline once a day. Treatments for all groups were given at the same time. Rats in all groups were monitored physical changes and general performance. Each rat was weighed every two days, and the weight was recorded. Pelleted feed and clean drinking water were provided ad libitum throughout the period of study (7 days).From day one to day six, fasting blood-glucose determined daily after 4h fast, after which feeding was restored. Then postprandial glucose was assayed. Water supply was not disrupted at any stage of the study. On the 7th day, fasting and postprandial (30 min, 60 min and 120 min) blood glucose, as well as C peptide insulin and intestinal α-glucosidase activities were determined.

Assay of α-glucosidase activity

The rats were sacrificed under anaesthesia, and the intestinal contents were cleared. The mucous membrane lining of the small intestine was carefully scraped onto an ice plate, and added to phosphate buffer, pH 6.8 in a volume ratio of 5:1 (buffer : mucous membrane lining). The mixture was centrifuged (5000 rpm) at 4 °C for 20min, and the supernatant was preserved at -20 °C prior to use in the assay of α-glucosidase activity. The enzyme was assayed with Sigma-Aldrich kits (Art. No. MAK123) according to manufacturer’s instructions.

Assay of C-peptide and insulin

Serum C peptide and insulin were determined by enzyme-linked immunosorbate assay (ELISA).
Statistical analysis

Statistical significance was evaluated by one-way ANOVA using SPSS 21 (SPSS Institute, Cary, NC, USA). $P < 0.05$ was set as statistically significant.

RESULTS

There were no significant differences in fasting blood glucose, C-peptide and insulin between groups ($p > 0.05$) (Figure 1, Figure 2 and Figure 3). In addition, no significant difference was found in postprandial glucose levels between the groups at 120 min after feeding from days 1 to 7 ($p > 0.05$, Figure 3B).

In addition, there were no significant differences in postprandial glucose 120 min after feeding from day 1 to day 6 ($p > 0.05$) (Figure 3B). However, intestinal $\alpha$-glucosidase activity results at 0, 30, 60 and 120 min in the rhubarb group (1759.2, 1812.8, 1379.8 and 772.1 U, respectively) and acarbose (1759.2, 1260.1, 1126.5 and 599.2 U, respectively) groups showed initial increase from time zero to 30 min, followed by significant decline from 60 min to 120 min ($p < 0.05$). After 120 min, $\alpha$-glucosidase activity in each of the two groups was significantly lower than control value (1200 U) ($p < 0.05$).

DISCUSSION

Prior to the administration of rhubarb and Arcabose, fasting blood glucose levels of rats in three groups were all $\geq 11.0$mmol/L, and their insulin or C-peptide levels were not related to feeding. Most of the rats had damaged islet cells and hypoinsulinism. These data indicate that type 1 diabetes model was successfully established in the rats.

Treatment with rhubarb and Acarbose brought about significant reduction in the activity of $\alpha$-glucosidase.
postprandial intestinal α-glucosidase. It is interesting to note that there was no significant difference in α-glucosidase activity between the rhubarb and Acarbose groups. This implies that rhubarb has the same level of efficacy as Acarbose. Thus rhubarb could be developed into a new type of hypoglycemic agent with similar α-glucosidase inhibitory activity. This will have the advantage of overcoming the gastrointestinal discomfort usually associated with use of Acarbose[4].

The inhibitory effect of rhubarb may be due to anthroquiones, which are its major phytochemical components. Strangely, the activity of α-glucosidase of rats in these two groups was abnormally higher than those of rats in the control group. Further studies are needed to verify whether this phenomenon was due to rebound effect or not.

Pipataline, sesamin, and pellitorine, which inhibit the activity of α-glucosidase, have been applied in the prevention and treatment of diabetes [15]. Many plants in traditional Chinese medicine can significantly inhibit α-glucosidase. MCQ et al have carried out a prospective study on the treatment of type 2 diabetes with natural chemical compounds extracted from plants instead synthetic α-glucosidase activity inhibitors [16]. Studies have shown that the anthroquinones in rhubarb inhibit α-glucosidase activity in competitively [16,17]. The results obtained in this study further confirm that rhubarb possesses α-glucosidase inhibitory activity.

Some studies have shown that the changes in the composition of intestinal microflora may be the primary cause of α-glucosidase activity inhibition. For example, Streptomyces bacteria [18] and fermented black bean [19] have been reported as inhibitors of α-glucosidase activity. Thus it is not unlikely that the inhibition brought about by rhubarb might be linked, partially at least, to changes in composition of intestinal flora.

CONCLUSION

The inhibitory effect of rhubarb extract on intestinal α-glucosidase, which was comparable to that of acarbose, confirms the anti-diabetic potential of rhubarb. This finding is significant in the light of efforts to find replacement drugs with similar efficacy but less toxicity than Acarbose in the treatment of type 1 diabetes.

REFERENCES


DECLARATIONS

Acknowledgement

The authors thank Key Scientific Projects of Shantou City for financial support (no. C201400126) and Laboratory Animal Center of Guangzhou Province for technical support.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/redirect), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
7. Kumar P, Vgm P. A Randomized Double-Masked Study of 50 mg of Acarbose versus 0.2 mg Voglibose in Overweight Type 2 Diabetes Patients Age Between 30 and 50 Years Having Isolated Postprandial Glycemia. Indian J Clin Pract 2014; 24(9).